for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Rockwell Medical Inc

RMTI.OQ

Latest Trade

2.46USD

Change

0.07(+2.93%)

Volume

29,990

Today's Range

2.37

 - 

2.54

52 Week Range

2.19

 - 

6.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.39
Open
2.37
Volume
29,990
3M AVG Volume
6.49
Today's High
2.54
Today's Low
2.37
52 Week High
6.88
52 Week Low
2.19
Shares Out (MIL)
63.82
Market Cap (MIL)
152.54
Forward P/E
-3.68
Dividend (Yield %)
--

Latest Developments

More

Rockwell Medical Says Q2 Loss Per Share $0.18

Rockwell Medical Announces Acceptance By FDA Of New Drug Application For I.V. Triferic

Rockwell Medical Comments On Preliminary Proposed CMS Rule

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Rockwell Medical Inc

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company's drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

Industry

Medical Equipment & Supplies

Contact Info

30142 S Wixom Rd

+1.248.9609009

http://www.rockwellmed.com

Executive Leadership

Benjamin Wolin

Independent Chairman of the Board

Stuart M. Paul

President, Chief Executive Officer, Director

Angus W. Smith

Chief Financial Officer

Jim McCarthy

Senior Vice President - Corporate and Business Development

Paul E. McGarry

Principal Accounting Officer, Vice President, Corporate Controller

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.390

2017

-0.510

2018

-0.610

2019(E)

-0.643
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.39
Price To Book (MRQ)
5.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.45
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-92.00
Return on Equity (TTM)
-67.65

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up